Pulmonary mucosa-associated lymphoid tissue lymphoma revisited

Eur Respir J. 2016 Apr;47(4):1244-60. doi: 10.1183/13993003.01701-2015. Epub 2016 Jan 21.

Abstract

This general review sought to clarify the pathophysiological, diagnostic, prognostic, and therapeutic features of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.MALT lymphoma is the most common pulmonary B-cell lymphoma, which usually occurs in the context of acquired MALT. The disease is slow-growing with an asymptomatic chronic alveolar opacity visible on radiography. Diagnosis requires tissue samples that should be retrieved using minimally invasive techniques, such as bronchoscopy or computed tomography-guided biopsies. The pathophysiology includes cytogenetic abnormalities and autoimmune diseases, whereas an association with a chronic pulmonary infection is still suspected but not yet demonstrated. Disease prognosis is typically excellent and the current available treatments are discussed in this review, including the decision not to treat, surgery, and single- or double-agent chemotherapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Bronchi / pathology
  • Bronchoalveolar Lavage
  • Bronchoscopy
  • Diagnosis, Differential
  • Humans
  • Lung / metabolism
  • Lymphoid Tissue / pathology*
  • Lymphoma, B-Cell, Marginal Zone / genetics
  • Lymphoma, B-Cell, Marginal Zone / immunology*
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Prognosis
  • Respiratory Mucosa / metabolism*
  • Tomography, X-Ray Computed